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Abstract (within 1000 words) 
Purpose 
   Acute kidney injury (AKI) is a life-threatening syndrome, commonly seen in hospitalized patients. AKI  
could result in death or chronic complications even after recovery. Inflammation following the initial injury 
exaggerates the disease progression, in which myeloid cells such as monocytes and neutrophils, play critical 
causative roles. Thus, targeting myeloid cell activation and migration gives a protective effect in AKI.  
   DNAM-1 is a co-stimulatory immunoreceptor, expressed on human and mice NK cells, CD4+ T cells, 
CD8+ T cells, subsets of macrophages, monocytes and B cells. Initial studies by Akira Shibuya show that 
DNAM-1 activates the cell-mediated cytotoxicity and cytokines production of NK cells and CD8+ T cells. 
However, its contribution to myeloid cells, including monocytes, are not fully understood.  
   Therefore, this study aims to elucidate the following points. First, investigate the expression pattern of 
DNAM-1 on myeloid cells in human and mice peripheral blood, in comparison with that in the spleen, which 
was already reported. Second, examining the function of DNAM-1 on expressing myeloid cells. Third, 
explore the involvement of DNAM-1 in acute kidney injury, the disease condition wherein myeloid cells 
play the key roles. Also, research the mechanism by which DNAM-1 performs its disease regulation. 
 
Materials and methods 
    DNAM-1 expression on immune cells was analyzed by flow cytometry. First, healthy donors’ blood 
was used to isolate human immune cells while mice blood and spleens were used to prepare for murine cells. 
Then, isolated cells were fluorescently labeled using antibodies specific for differential cell surface markers 
and DNAM-1. Therefore, DNAM-1 expression on different populations of cells could be acquired. 
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   The physiological function of DNAM-1 in inflammatory monocytes was examined using the in vitro 
adherence assay. CFSE (5(6)-Carboxyfluorescein N-hydroxysuccinimidyl ester) labeled inflammatory 
monocytes were incubated with CD155 – the stress-induced ligand of DNAM-1 – expressing transfectants; 
after washing, remaining CFSE positive cells indicated adhered cells and were quantified using Keyence 
microscopy. 
    A murine model of unilateral warm ischemia-reperfusion injury (IRI) resembles AKI in human was 
perform to explore the in vivo physiological function of DNAM-1. In brief, mice were anesthetized, and 
their right kidneys were cut-off while the left kidneys were clamped to induce ischemia. After a particular 
time, releasing clamps initiated the reperfusion of blood cells, and kidney injury progressed. The outcome 
was renal dysfunction measured by plasma creatinine and blood urine nitrogen (BUN). 
 
   To investigate whether DNAM-1 promoted AKI via regulating monocytes migration from blood to 
tissue, several strategies were used. First, monocytes accumulated in kidneys after IRI were quantified by 
flow cytometry. Next, inflammatory cytokines produced by sorted monocytes from organs was measured by 
quantitative PCR (polymerase chain reaction). The systemic cytokines increased after IRI was detected in 
the plasma by cytometric bead array.   
     
Results 
   Firstly, this study comprehensively investigated the DNAM-1 expression pattern in peripheral blood 
cells, in comparison with that of the previously reported splenocytes. It revealed that the expression of 
DNAM-1 is selective on the inflammatory monocytes but not patrolling monocytes; which was conserved 
in both human and mouse, suggesting DNAM-1 is an evolutionary molecule in inflammatory monocytes.  
   Neutrophils and eosinophils also express DNAM-1 at a moderate level, which was not seen in 
splenocytes; however, lymphoid cells express DNAM-1 at the level as much as observed in spleen, 
suggesting cell type-specific and tissue-specific characteristics of DNAM-1 expression. 
   DNAM-1 deficient (CD226-/-) inflammatory monocytes has attenuated ability to adhere to CD155, 
DNAM-1 ligand, expressing transfectants in vitro compared to wild type (WT) cells. Supportively, inhibiting 
DNAM-1 and CD155 interaction by monoclonal antibodies also lowered the adhered cell number in the 
adherence assay compared with isotype control. These data suggested that DNAM-1 – CD155 interaction is 
required for inflammatory monocytes mobility characteristics, particularly the adhesion behavior.  
   DNAM-1 deficient mice showed milder renal dysfunction induced by IRI in comparison with WT mice, 
indicating DNAM-1 exaggerated acute kidney injury. Furthermore, the accumulation of immune cells 
following ischemia-reperfusion including monocytes and neutrophils were reduced in CD226-/- mice, 
suggesting that DNAM-1 promoted inflammation in AKI.    
  
Discussion 
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   Although DNAM-1 expression on lymphoid cells was consistent between organs, it was diverse in 
myeloid cells, depending on cell types and tissue specificity. Myeloid cells are highly heterogeneous with 
multiple subsets in an organ. So, DNAM-1 could be one of those molecules which determine expression 
patterns and the physiological distinction between subgroups, to be specific monocytes sub-populations in 
this study. It is of interest to identify which master regulator determines DNAM-1 expression, developmental 
window and functional requirement of DNAM-1 on myeloid sub-types. 
   DNAM-1 function on monocytes’ migration was reported in human cells in vitro, but this was the first 
to describe DNAM-1 involvement in mouse monocytes' adherence, which is corroborating with previous 
data of human cells, suggesting DNAM-1 knockout mice as a useful tool to investigate physiological 
function of DNAM-1 in murine disease models. 
   Even though CD155 transfectants were used for the functional in vitro assay, primary cells, including 
endothelial cells, also express CD155. Also, the expression was reported to upregulate in stress-induced 
conditions, including tissue damage. Therefore, DNAM-1 expressing inflammatory monocytes might 
interact with CD155 expressing endothelial cells for the trans-endothelial extravasation after IRI induction 
in this study.   
   There exists a correlation between attenuated kidney injury and the decrease of myeloid cells percentage 
and number in the injured site. Whether DNAM-1 promoted IRI induced inflammation by directly regulating 
myeloid cells migration is unclear, despite the dependency of monocytes adhesion on DNAM-1 in vitro. 
Therefore, other possibilities should be examined such as DNAM-1 regulated inflammatory cytokines 
production or DNAM-1 indirectly controlling myeloid cell migration via different cell types.  
  
   Though this study showed that DNAM-1 possesses a pathogenic effect in the acute phase of kidney 
injury, it is unknown what would happen at the late stage of this model. For instance, whether chronic kidney 
inflammation such as fibrosis, could be altered by DNAM-1 deficiency. Also, it is of interest to investigate 
DNAM-1 involvement in other ischemia-related diseases such as brain stroke and heart attack. 
    
 
 
 
 
 
 
 
 
